| Description | FOXO1 Human Pre-designed siRNA Set A contains three designed siRNAs for FOXO1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components FOXO1 siRNA-1: 5 nmol (HPLC) FOXO1 siRNA-2: 5 nmol (HPLC) FOXO1 siRNA-3: 5 nmol (HPLC) siRNA Negative Control:FOXO1 Human Pre-designed siRNA Set A contains three designed siRNAs for FOXO1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components FOXO1 siRNA-1: 5 nmol (HPLC) FOXO1 siRNA-2: 5 nmol (HPLC) FOXO1 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Inquire | The Leuconostoc GPDH exhibits dual coenzyme specificity, namely NAD and NADP (Olive and Levy, Biochem., 6, 730 730, 1967). When assayed under conditions that are optimal for the particular coenzyme, the ratio of observed catalytic activity is NAD/NADP = 1.8 | Biochemical Test:SDS-PAGE (purity > 80%); Western blot with patient sample.Calculated Isoelectric Point:pH 4.19 | Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis... Read More |